newsfilter
← Latest News
Business Wire·

Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Raymond J. Deshaies, Ph.D.,